Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 225 entries
Sorted by: Best Match Show Resources per page
Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy

Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H.
PMID: 35017119
Transplant Cell Ther. 2022 Jan 08; doi: 10.1016/j.jtct.2022.01.003. Epub 2022 Jan 08.

BACKGROUND: Although tacrolimus and sirolimus (TAC/SIR) is an accepted graft-versus-host disease (GVHD) prophylaxis following allogeneic hematopoietic cell transplant (HCT), toxicity from this regimen can lead to premature discontinuation of immunosuppression. There are limited studies reporting outcomes and subsequent treatment...

Cite
Mirza AS, Tandon A, Jenneman D, et al. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022;doi: 10.1016/j.jtct.2022.01.003.
Mirza, A. S., Tandon, A., Jenneman, D., Cao, S., Brimer, T., Kumar, A., Kidd, M., Khimani, F., Faramand, R., Mishra, A., Liu, H., Nishihori, T., Perez, L., Lazaryan, A., Bejanyan, N., Nieder, M., Pidala, J., & Elmariah, H. (2022). Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2022.01.003
Mirza, Abu-Sayeef, et al. "Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation." Transplantation and cellular therapy vol. (2022). doi: https://doi.org/10.1016/j.jtct.2022.01.003
Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-Versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jan 08; doi: 10.1016/j.jtct.2022.01.003. Epub 2022 Jan 08. PMID: 35017119.
Copy Download .nbib Format: NLM
Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.

Transplantation and cellular therapy

Janakiram M, Arora N, Bachanova V, Miller JS.
PMID: 34634499
Transplant Cell Ther. 2021 Oct 08; doi: 10.1016/j.jtct.2021.10.001. Epub 2021 Oct 08.

Autologous stem cell transplantation (ASCT) is an important component of treatment of multiple myeloma (MM). The post-ASCT setting offers a unique opportunity to increase myeloma specific immunity through enhancement of T and NK cell responses. The vast array of...

Cite
Janakiram M, Arora N, Bachanova V, et al. Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.10.001.
Janakiram, M., Arora, N., Bachanova, V., & Miller, J. S. (2021). Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.10.001
Janakiram, Murali, et al. "Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.10.001
Janakiram M, Arora N, Bachanova V, Miller JS. Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Transplant Cell Ther. 2021 Oct 08; doi: 10.1016/j.jtct.2021.10.001. Epub 2021 Oct 08. PMID: 34634499.
Copy Download .nbib Format: NLM
Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic.

Transplantation and cellular therapy

Purtill D, Hutchins C, Kennedy G, McClean A, Fraser C, Shaw PJ, Chiappini P, Tao H, Ma DD, Kabani K, Bai L, Greenwood M, Bajel A, O'Flaherty E, Curtis DJ, Purins L, Perera T, Tan S, Butler A, Micklethwaite K, Antonenas V, Gottlieb D, Hamad N.
PMID: 34571211
Transplant Cell Ther. 2021 Dec;27(12):1022.e1-1022.e6. doi: 10.1016/j.jtct.2021.09.012. Epub 2021 Sep 24.

Changes to donor availability, collection center capacity, and travel restrictions during the early phase of the COVID-19 pandemic led to routine cryopreservation of most unrelated donor products for hematopoietic transplantation prior to the recipient commencing the conditioning regimen. We...

Cite
Purtill D, Hutchins C, Kennedy G, et al. Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transplant Cell Ther. 2021;27(12):1022.e1-1022.e6doi: 10.1016/j.jtct.2021.09.012.
Purtill, D., Hutchins, C., Kennedy, G., McClean, A., Fraser, C., Shaw, P. J., Chiappini, P., Tao, H., Ma, D. D., Kabani, K., Bai, L., Greenwood, M., Bajel, A., O'Flaherty, E., Curtis, D. J., Purins, L., Perera, T., Tan, S., Butler, A., Micklethwaite, K., Antonenas, V., Gottlieb, D., & Hamad, N. (2021). Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transplantation and cellular therapy, 27(12), 1022.e1-1022.e6. https://doi.org/10.1016/j.jtct.2021.09.012
Purtill, Duncan, et al. "Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic." Transplantation and cellular therapy vol. 27,12 (2021): 1022.e1-1022.e6. doi: https://doi.org/10.1016/j.jtct.2021.09.012
Purtill D, Hutchins C, Kennedy G, McClean A, Fraser C, Shaw PJ, Chiappini P, Tao H, Ma DD, Kabani K, Bai L, Greenwood M, Bajel A, O'Flaherty E, Curtis DJ, Purins L, Perera T, Tan S, Butler A, Micklethwaite K, Antonenas V, Gottlieb D, Hamad N. Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transplant Cell Ther. 2021 Dec;27(12):1022.e1-1022.e6. doi: 10.1016/j.jtct.2021.09.012. Epub 2021 Sep 24. PMID: 34571211.
Copy Download .nbib Format: NLM
Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.

Transplantation and cellular therapy

Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S.
PMID: 34954151
Transplant Cell Ther. 2021 Dec 22; doi: 10.1016/j.jtct.2021.12.009. Epub 2021 Dec 22.

Previous Japanese studies have shown that bone marrow transplantation (BMT) is associated with better survival compared with peripheral blood stem cell transplantation (PBSCT) from a matched related donor (MRD). PBSCT recipients have shown higher incidences of severe graft-versus-host disease...

Cite
Miyao K, Kuwatsuka Y, Murata M, et al. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.12.009.
Miyao, K., Kuwatsuka, Y., Murata, M., Nagafuji, K., Teshima, T., Takeuchi, Y., Shiratori, S., Najima, Y., Uchida, N., Tanaka, M., Sawa, M., Ota, S., Fukuda, T., Ozawa, Y., Kako, S., Kawakita, T., Ara, T., Tanaka, J., Kanda, Y., Atsuta, Y., Kanda, J., Terakura, S. (2021). Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.12.009
Miyao, Kotaro, et al. "Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.12.009
Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplant Cell Ther. 2021 Dec 22; doi: 10.1016/j.jtct.2021.12.009. Epub 2021 Dec 22. PMID: 34954151.
Copy Download .nbib Format: NLM
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy

Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ.
PMID: 34852305
Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.014. Epub 2021 Nov 28.

BACKGROUND: Chimeric antigen receptor (CAR) T cells achieve response and durable remission in patients with relapsed/refractory (R/R) B cell malignancies. Following collection of patient T cells, chemotherapy ("bridging chemotherapy") is utilized during the manufacture of CAR T cells. However,...

Cite
Shahid S, Ramaswamy K, Flynn J, et al. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.014.
Shahid, S., Ramaswamy, K., Flynn, J., Mauguen, A., Perica, K., Park, J. H., Forlenza, C. J., Shukla, N. N., Steinherz, P. G., Margossian, S. P., Boelens, J. J., Kernan, N. A., & Curran, K. J. (2021). Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.014
Shahid, Sanam, et al. "Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.014
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.014. Epub 2021 Nov 28. PMID: 34852305.
Copy Download .nbib Format: NLM
Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency.

Transplantation and cellular therapy

Laberko A, Idarmacheva A, Glushkova S, Pershin D, Shelikhova L, Maschan M, Maschan A, Balashov D.
PMID: 34875404
Transplant Cell Ther. 2021 Dec 04; doi: 10.1016/j.jtct.2021.11.022. Epub 2021 Dec 04.

We recently demonstrated that TCRαβ+/CD19+ graft depletion successfully prevents severe acute and chronic graft-versus-host disease (GVHD) in pediatric patients with primary immunodeficiencies (PID) receiving transplants from both matched unrelated and mismatched related donors. However, in all patients, short-term post-hematopoietic...

Cite
Laberko A, Idarmacheva A, Glushkova S, et al. Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.022.
Laberko, A., Idarmacheva, A., Glushkova, S., Pershin, D., Shelikhova, L., Maschan, M., Maschan, A., & Balashov, D. (2021). Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.022
Laberko, Alexandra, et al. "Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.022
Laberko A, Idarmacheva A, Glushkova S, Pershin D, Shelikhova L, Maschan M, Maschan A, Balashov D. Post-Transplantation Immunosuppression After TCRΑβ/CD19 Graft Depletion Does Not Improve HSCT Outcomes in Primary Immunodeficiency. Transplant Cell Ther. 2021 Dec 04; doi: 10.1016/j.jtct.2021.11.022. Epub 2021 Dec 04. PMID: 34875404.
Copy Download .nbib Format: NLM
A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.

Transplantation and cellular therapy

Andermann TM, Fouladi F, Tamburini FB, Sahaf B, Tkachenko E, Greene C, Buckley MT, Brooks EF, Hedlin H, Arai S, Mackall CL, Miklos D, Negrin RS, Fodor AA, Rezvani AR, Bhatt AS.
PMID: 34274493
Transplant Cell Ther. 2021 Nov;27(11):932.e1-932.e11. doi: 10.1016/j.jtct.2021.07.009. Epub 2021 Jul 16.

Alterations of the gut microbiota after allogeneic hematopoietic cell transplantation (allo-HCT) are a key factor in the development of transplant-related complications such as graft-versus-host disease (GVHD). Interventions that preserve the gut microbiome hold promise to improve HCT-associated morbidity and...

Cite
Andermann TM, Fouladi F, Tamburini FB, et al. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplant Cell Ther. 2021;27(11):932.e1-932.e11doi: 10.1016/j.jtct.2021.07.009.
Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., Buckley, M. T., Brooks, E. F., Hedlin, H., Arai, S., Mackall, C. L., Miklos, D., Negrin, R. S., Fodor, A. A., Rezvani, A. R., & Bhatt, A. S. (2021). A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplantation and cellular therapy, 27(11), 932.e1-932.e11. https://doi.org/10.1016/j.jtct.2021.07.009
Andermann, Tessa M, et al. "A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial." Transplantation and cellular therapy vol. 27,11 (2021): 932.e1-932.e11. doi: https://doi.org/10.1016/j.jtct.2021.07.009
Andermann TM, Fouladi F, Tamburini FB, Sahaf B, Tkachenko E, Greene C, Buckley MT, Brooks EF, Hedlin H, Arai S, Mackall CL, Miklos D, Negrin RS, Fodor AA, Rezvani AR, Bhatt AS. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplant Cell Ther. 2021 Nov;27(11):932.e1-932.e11. doi: 10.1016/j.jtct.2021.07.009. Epub 2021 Jul 16. PMID: 34274493; PMCID: PMC8556222.
Copy Download .nbib Format: NLM
CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse.

Transplantation and cellular therapy

Sun G, Tang B, Wan X, Yao W, Song K, Tu M, Geng L, Qiang P, Wu Y, Zhu L, Wu Y, Liu H, Zhu X, Sun Z.
PMID: 34839013
Transplant Cell Ther. 2021 Nov 25; doi: 10.1016/j.jtct.2021.11.011. Epub 2021 Nov 25.

BACKGROUND: Several studies have indicated that chimeric antigen receptor T-cell (CAR-T) therapy followed by allogeneic hematopoietic stem cell transplantation is beneficial for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Whether consolidative unrelated cord blood transplantation (UCBT) is suitable in...

Cite
Sun G, Tang B, Wan X, et al. CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.011.
Sun, G., Tang, B., Wan, X., Yao, W., Song, K., Tu, M., Geng, L., Qiang, P., Wu, Y., Zhu, L., Wu, Y., Liu, H., Zhu, X., & Sun, Z. (2021). CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.011
Sun, Guangyu, et al. "CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.011
Sun G, Tang B, Wan X, Yao W, Song K, Tu M, Geng L, Qiang P, Wu Y, Zhu L, Wu Y, Liu H, Zhu X, Sun Z. CAR-T cell therapy followed by unrelated cord blood transplantation for the treatment of relapsed/refractory B-cell ALL in children and young adults: superior survival but relatively high posttransplant relapse. Transplant Cell Ther. 2021 Nov 25; doi: 10.1016/j.jtct.2021.11.011. Epub 2021 Nov 25. PMID: 34839013.
Copy Download .nbib Format: NLM
Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children.

Transplantation and cellular therapy

Forlanini F, Zinter MS, Dvorak CC, Bailey-Olson M, Winestone LE, Shimano KA, Higham CS, Melton A, Chu J, Kharbanda S.
PMID: 34848362
Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.015. Epub 2021 Nov 28.

Allogeneic hematopoietic cell transplantation (HCT) can lead to considerable complications and treatment-related mortality (TRM); therefore, a detailed assessment of risks is essential. The Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) can predict both TRM and overall survival (OS). Although the HCT-CI...

Cite
Forlanini F, Zinter MS, Dvorak CC, et al. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.015.
Forlanini, F., Zinter, M. S., Dvorak, C. C., Bailey-Olson, M., Winestone, L. E., Shimano, K. A., Higham, C. S., Melton, A., Chu, J., & Kharbanda, S. (2021). Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.015
Forlanini, Federica, et al. "Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.015
Forlanini F, Zinter MS, Dvorak CC, Bailey-Olson M, Winestone LE, Shimano KA, Higham CS, Melton A, Chu J, Kharbanda S. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.015. Epub 2021 Nov 28. PMID: 34848362.
Copy Download .nbib Format: NLM
Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism - A BMTSS Report.

Transplantation and cellular therapy

Wadhwa A, Chen Y, Hageman L, Schlichting E, Funk E, Hicks J, Balas N, Siler A, Wu J, Francisco L, Holmqvist A, Gupta A, Lund T, Orchard PJ, Armenian S, Arora M, Bhatia S.
PMID: 34879288
Transplant Cell Ther. 2021 Dec 05; doi: 10.1016/j.jtct.2021.11.023. Epub 2021 Dec 05.

BACKGROUND: Survival after blood or marrow transplantation (BMT) for Inborn Errors of Metabolism (IEM) is excellent; however, the burden of morbidity in long-term survivors of BMT for IEM remains understudied.OBJECTIVES: Examine the risk of chronic health conditions (CHC) in...

Cite
Wadhwa A, Chen Y, Hageman L, et al. Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism - A BMTSS Report. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.023.
Wadhwa, A., Chen, Y., Hageman, L., Schlichting, E., Funk, E., Hicks, J., Balas, N., Siler, A., Wu, J., Francisco, L., Holmqvist, A., Gupta, A., Lund, T., Orchard, P. J., Armenian, S., Arora, M., & Bhatia, S. (2021). Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism - A BMTSS Report. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.023
Wadhwa, Aman, et al. "Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism - A BMTSS Report." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.023
Wadhwa A, Chen Y, Hageman L, Schlichting E, Funk E, Hicks J, Balas N, Siler A, Wu J, Francisco L, Holmqvist A, Gupta A, Lund T, Orchard PJ, Armenian S, Arora M, Bhatia S. Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism - A BMTSS Report. Transplant Cell Ther. 2021 Dec 05; doi: 10.1016/j.jtct.2021.11.023. Epub 2021 Dec 05. PMID: 34879288.
Copy Download .nbib Format: NLM
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy

Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ.
PMID: 34852305
Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.014. Epub 2021 Nov 28.

Chimeric antigen receptor (CAR) T cells achieve response and durable remission in patients with relapsed/refractory (R/R) B cell malignancies. Following collection of patient T cells, chemotherapy ("bridging chemotherapy") is utilized during the manufacture of CAR T cells. However, the...

Cite
Shahid S, Ramaswamy K, Flynn J, et al. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2021;doi: 10.1016/j.jtct.2021.11.014.
Shahid, S., Ramaswamy, K., Flynn, J., Mauguen, A., Perica, K., Park, J. H., Forlenza, C. J., Shukla, N. N., Steinherz, P. G., Margossian, S. P., Boelens, J. J., Kernan, N. A., & Curran, K. J. (2021). Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplantation and cellular therapy, . https://doi.org/10.1016/j.jtct.2021.11.014
Shahid, Sanam, et al. "Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia." Transplantation and cellular therapy vol. (2021). doi: https://doi.org/10.1016/j.jtct.2021.11.014
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2021 Nov 28; doi: 10.1016/j.jtct.2021.11.014. Epub 2021 Nov 28. PMID: 34852305.
Copy Download .nbib Format: NLM
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.

Transplantation and cellular therapy

Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales MA, Sauter C, Ponce DM.
PMID: 34029766
Transplant Cell Ther. 2021 Nov;27(11):920.e1-920.e9. doi: 10.1016/j.jtct.2021.05.008. Epub 2021 May 21.

Graft-versus-host disease (GVHD) is a frequent complication in the first year after allogeneic stem cell transplantation (allo-HCT). Recipients of reduced-intensity (RI) or nonmyeloablative (NMA) conditioning combined with calcineurin inhibitor (CNI)-based GVHD prophylaxis frequently develop GVHD in the context of...

Cite
Rodriguez N, Lee J, Flynn L, et al. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021;27(11):920.e1-920.e9doi: 10.1016/j.jtct.2021.05.008.
Rodriguez, N., Lee, J., Flynn, L., Murray, F., Devlin, S. M., Soto, C., Cho, C., Dahi, P., Giralt, S., Perales, M. A., Sauter, C., & Ponce, D. M. (2021). Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplantation and cellular therapy, 27(11), 920.e1-920.e9. https://doi.org/10.1016/j.jtct.2021.05.008
Rodriguez, Natasia, et al. "Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation." Transplantation and cellular therapy vol. 27,11 (2021): 920.e1-920.e9. doi: https://doi.org/10.1016/j.jtct.2021.05.008
Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales MA, Sauter C, Ponce DM. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021 Nov;27(11):920.e1-920.e9. doi: 10.1016/j.jtct.2021.05.008. Epub 2021 May 21. PMID: 34029766.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 225 entries